I 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The company Abbott Laboratories Ltd, UK, submitted on 31 July 1998, an application for Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA), for Synagis, 
in accordance with the centralised Procedure for the medicinal product Synagis (palivizumab) falling 
within the scope of Part A of the Annex to Council Regulation No (EC) 2309/93. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:   Dr. G. Jensen  
Co-Rapporteur:   Dr. Haase (Dr. Schaeffner) 
Licensing status: 
2. 
3. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Synagis has been given a Marketing Authorisation in United States on 19 June 1998. 
2. 
Steps taken for the assessment of the product 
The Rapporteur’s initial assessment report was circulated to all members of the CPMP on  
2 November 1998. 
The Co-rapporteur’s initial assessment report was circulated to the members of the CPMP on  
2 November 1998. 
The BWP during its meeting on 9 December 1998 prepared a recommendation to the CPMP on 
quality aspects of the assessment report. 
The  CPMP  during  its  meeting  on  15-17  December  1998  finalised  the  list  of  questions  to  be 
addressed by the company.  
The CPMP consolidated list of questions was sent to the company on 17 December 1998 (Stop 
of the clock).  
The CPMP requested an inspection of the manufacturing site of Boehringer Ingelheim Pharma 
KG on the basis of the need to assess GMP compliance. The inspection took place on  
8-10 March 1999. The inspection report was forwarded to EMEA on 22 April 1998.  
The  general  impression  of  the  Quality  Assurance  System  and  compliance  with  the  EU  GMP 
rules is positive.  
The applicant submitted the responses to the consolidated CPMP list of questions on  
26 February 1999 and the clock restarted. 
The  Rapporteur/Co-Rapporteur  joint  assessment  report  on  the  applicant’s  responses  and  joint 
recommendation was circulated to CPMP members on 31 March 1999. 
The  CPMP  during  its  meeting  on  21  April  1999  discussed  the  joint  assessment  report  and 
decided to stop the clock for an oral presentation on clinical issues in May. A list of outstanding 
clinical and quality issues was adopted by the CPMP . 
The applicant submitted responses to the quality outstanding points on 30 April 1999.  
The  Rapporteur’s/Co-rapporteur’s  joint  assessment  report  on  the  responses  to  the  quality 
questions was circulated on 6 May 1999. 
The BWP during their meeting on 11 May 1999 prepared a recommendation to the CPMP on 
the outstanding quality aspects with particular reference to virus validation issues . 
Oral explanations were given by the Applicant on 18 May 1999. 
Undertaking signed by the Company on the follow-up measures on 19 May 1999.   
1/2 
EMEA 2004 
 
  
 
 
• 
• 
During the meeting on 17-19 May 1999 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Synagis on 19 May 1999. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 13 August 1999. 
2/2 
EMEA 2004 
 
 
